Feng Gao

Medicine & Life Sciences

1. Breast Neoplasms 100%
2. Neoplasms 86%
3. Survival 80%
4. Triple Negative Breast Neoplasms 64%
5. Endometrial Neoplasms 63%
6. Non-Small Cell Lung Carcinoma 60%
7. Neurofibromatosis 1 55%
8. Recurrence 50%
9. Therapeutics 35%
10. Drug Therapy 31%
11. Open Angle Glaucoma 30%
12. Segmental Mastectomy 29%
13. Lymph Nodes 27%
14. Multiple Myeloma 27%
15. Progression-Free Survival 27%
16. Adenocarcinoma 26%
17. Breast 25%
18. plerixafor octahydrochloride 23%
19. Disease-Free Survival 23%
20. Mutation 23%
21. Transplants 22%
22. Confidence Intervals 22%
23. Ocular Hypertension 22%
24. Clinical Trials 22%
25. Uterine Cervical Neoplasms 22%
26. Cell Biology 21%
27. Radiation 21%
28. Cell Transplantation 21%
29. Child 21%
30. Mastectomy 21%
31. Acute Myeloid Leukemia 20%
32. Hematopoietic Stem Cells 20%
33. temsirolimus 19%
34. Carcinoma 19%
35. Allogeneic Cells 19%
36. Non-Hodgkin's Lymphoma 19%
37. Randomized Controlled Trials 19%
38. Hysterectomy 19%
39. Positron-Emission Tomography 18%
40. Atypical Squamous Cells of the Cervix 18%
41. Bevacizumab 17%
42. Ovarian Neoplasms 17%
43. Neoplasm Metastasis 17%
44. Mammaglobin A 17%
45. Carboplatin 17%
46. Maximum Tolerated Dose 16%
47. Natural Killer Cells 16%
48. Estrogen Receptors 16%
49. Necrosis 16%
50. Biomarkers 16%